Amarantus Subsidiary MANF Therapeutics Announces Positive Independent Peer-Reviewed Pre-Clinical Data for MANF in Parkinson's..
January 29 2018 - 9:00AM
InvestorsHub NewsWire
Amarantus
Subsidiary MANF Therapeutics Announces Positive Independent
Peer-Reviewed Pre-Clinical Data for MANF in Parkinson’s
Disease
- Data show in-animal increases in free-release
dopamine and dopamine turnover
San Francisco,
CA -- January 29, 2018 -- InvestorsHub NewsWire
-- Amarantus Bioscience Holdings,
Inc. (OTCPK:
AMBS), a
US-based biotechnology holding company with wholly-owned
subsidiaries developing first-in-class orphan neurologic,
regenerative medicine and ophthalmic therapies, today disclosed
that its wholly-owned subsidiary MANF Therapeutics announced the
publication of an independent peer-reviewed article entitled
“Mesencephalic Astrocyte-Derived Neurotrophic Factor (MANF)
Elevates Stimulus-Evoked Release of Dopamine in Freely-Moving
Rats” in the scientific journal Molecular Neurobiology. MANF
is in pre-clinical development for the treatment of orphan
ophthalmological disorders, Glaucoma and Parkinson’s
disease.
The published data show that 1 week after MANF
treatment, there is an increased release of dopamine, as well as
increased dopamine turnover, in the rat striatum in response to
stimulus, as measured by brain microdialysis. These data are
significant because they propose a unique mechanism of action for
MANF in Parkinson’s disease that provides a rationale for
potentially improved treatment efficacy with MANF versus other
neurotrophic factors in-development. Currently-approved drugs for
Parkinson’s disease primarily target dopamine replacement as their
mechanism of action. Disease-modifying drugs, such as neurotrophic
factors, primarily target the rescue of the dopaminergic neurons
that degenerate in Parkinson’s disease. A treatment that could both
rescue dopaminergic neurons and increase dopamine release could be
a significant improvement over other approaches in treating
Parkinson’s disease.
A link to the abstract is available
here: https://link.springer.com/article/10.1007%2Fs12035-018-0872-8
.
About Amarantus Bioscience Holdings,
Inc.
Amarantus Bioscience Holdings (AMBS) is a biotechnology company
developing treatments and diagnostics for diseases in the areas of
neurology, regenerative medicine and orphan diseases through its
subsidiaries. AMBS’ wholly-owned subsidiary Elto Pharma,
Inc. has development rights to eltoprazine, a Phase
2b-ready small molecule indicated for Parkinson's disease
levodopa-induced dyskinesia, Alzheimer’s aggression and adult ADHD.
AMBS acquired the rights to the Engineered Skin Substitute program
(ESS), a regenerative medicine-based approach for treating severe
burns with full-thickness autologous skin grown in tissue culture
that is being pursued by AMBS’ wholly-owned subsidiary
Cutanogen Corporation. AMBS’ wholly-owned
subsidiary MANF Therapeutics, Inc. owns key intellectual property
rights and licenses from a number of prominent universities related
to the development of the therapeutic protein known as
mesencephalic astrocyte-derived neurotrophic factor (MANF).
MANF Therapeutics, Inc. is developing
MANF-based products as treatments for brain and ophthalmic
disorders. MANF was discovered by the Company’s Chief Scientific
Officer John Commissiong, PhD. Dr. Commissiong discovered MANF from
AMBS’ proprietary discovery engine PhenoGuard. AMBS also owns
approximately 80 million shares of Avant Diagnostics, Inc. via the
sale of its wholly-owned subsidiary Amarantus Diagnostics, Inc.
that occurred in May 2016.
For further information please
visit www.Amarantus.com, or
connect with the Amarantus on Facebook, LinkedIn, Twitter and Google+.
About MANF Therapeutics,
Inc.
MANF (mesencephalic-astrocyte-derived
neurotrophic factor) is believed to have broad potential because it
is a naturally-occurring protein produced by the body to
reduce/prevent apoptosis (cell death) in response to injury or
disease, via the unfolded protein response. By administering
exogenously produced MANF the body, Amarantus is seeking to use a
regenerative medicine approach to assist the body with higher
quantities of MANF when needed. Amarantus is the front-runner and
primary holder of intellectual property around MANF, and is
initially focusing on the development of MANF-based protein
therapeutics.
In April 2017, Amarantus incorporated the
wholly-owned subsidiary MANF Therapeutics, Inc. to focus on the
preclinical and clinical development of MANF. MANF's lead
indication is retinitis pigmentosa, and additional indications
including Parkinson's disease, diabetes and Wolfram's syndrome are
envisioned. Further applications for MANF may include Alzheimer's
disease, traumatic brain injury, myocardial infarction,
antibiotic-induced ototoxicity and certain other orphan
diseases.
Forward-Looking
Statements
Certain statements, other than purely historical
information, including estimates, projections, statements relating
to our business plans, objectives, and expected operating results,
and the assumptions upon which those statements are based, are
forward-looking statements. These forward-looking statements
generally are identified by the words "believes," "project,"
"expects," "anticipates," "estimates," "intends," "strategy,"
"plan," "may," "will," "would," "will be," "will continue," "will
likely result," and similar expressions. Forward-looking statements
are based on current expectations and assumptions that are subject
to risks and uncertainties which may cause actual results to differ
materially from the forward-looking statements. Our ability to
predict results or the actual effect of future plans or strategies
is inherently uncertain. Factors which could have a material
adverse effect on our operations and future prospects on a
consolidated basis include, but are not limited to: changes in
economic conditions, legislative/regulatory changes, availability
of capital, interest rates, competition, and generally accepted
accounting principles. These risks and uncertainties should also be
considered in evaluating forward-looking statements and undue
reliance should not be placed on such statements.
Amarantus Investor and Media
Contact:
Ascendant Partners, LLC
Richard Galterio
+1-732-410-9810
rich@ascendantpartnersllc.com
Source: Amarantus Bioscience Holdings,
Inc.
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Sep 2023 to Sep 2024